SNO Virtual Conference on Brain Metastases

Modern Therapies Offer a Way to Reach the Brain in HER2+ Metastatic Breast Cancer

August 14, 2020

In an interview with Targeted Oncology, Stephanie Weiss, MD, reviewed the treatment landscape for HER2-positive metastatic breast cancer and gave her predictions on how the paradigm will evolve for patients with brain metastases now that tucatinib has demonstrated efficacy.

Pooled Analysis Reveals Long-Term Effect on QoL and Cognitive Outcomes From Radiation for Brain Metastases

August 14, 2020

In the first pooled prospective study to show the long-term outcomes of cranial radiation in patients with limited brain metastases, it was observed that whole-brain radiotherapy was associated with worse cognitive outcomes and mixed quality of life compared with stereotactic radiosurgery for these patients over time, according to a presentation from Joshua Palmer, MD, at the 2020 Virtual Conference on Brain Metastases.

Cerebrospinal Fluid CTCs May Help Predict Outcomes in Leptomeningeal Disease

August 14, 2020

Quantification of circulating tumor cells in cerebrospinal fluid can be used to predict survival outcomes in patients with newly diagnosed leptomeningeal disease, according to the results of a retrospective analysis presented during the Society of Neuro-Oncology’s 2020 Virtual Conference on Brain Metastases .

Radiosurgery Improves Clinical Outcomes in Brain Metastasis Treatment

August 14, 2020

Joshua Palmer, MD, discusses a pooled analysis of 2 randomized clinical trials that compared how clinical outcomes and quality of life were impacted with stereotactic radiosurgery versus whole-brain radiation therapy in patients with brain metastases.

Tucatinib Combination Demonstrates Multiple Positive Responses in HER2-Positive Metastatic Breast Cancer

August 14, 2020

Multiple positive responses were observed in an exploratory efficacy analysis evaluating tucatinib in combination with trastuzumab and capecitabine in patients with previously treated HER2-positive metastatic breast cancer with brain metastases in the previously reported HER2CLIMB trial.

HER2CLIMB Regimen Delays CNS Progression in HER2+ Metastatic Breast Cancer

August 14, 2020

In an interview with Targeted Oncology following the SNO Brain Metastasis Meeting, Nancy Lin, MD, discussed the treatment of brain metastases in HER2-positive metastatic breast cancer in general, as well as the subgroup analysis of patients with brain metastases in the phase 2 HER2CLIMB clinical trial.